Sionna cuts 46% of staff, pivots to new CF drug combination
Tweet Send to a Friend
Sionna Therapeutics (Nasdaq: SION) announced plans to advance its SION-451 + SION-2222 dual combination into a Phase 2a proof-of-concept trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




